SPECIAL ARTICLE

World alliance against antibiotic resistance: The WAAAR declaration against antibiotic resistance

Jean Carlet, on behalf of the members of the WAAAR

Received 26 September 2014; accepted 3 October 2014 Available online 17 December 2014

KEYWORDS
Antibiotic resistance; WAAAR

PALABRAS CLAVE
Resistencia antibiótica; WAAAR

Abstract We must change how antibiotics are used and adopt proactive strategies, similar to those used to save endangered species. Preservation of the efficacy of antibiotics and to stabilization of antibiotic-susceptible bacterial ecosystems should be global goals.

© 2014 Elsevier España, S.L.U. and SEMICYUC. All rights reserved.

Alianza Mundial contra la resistencia antibiótica. Declaración contra la resistencia antibiótica

Resumen Debemos cambiar la forma como se utizan los antibióticos, adoptando estrategias proactivas, de igual manera que se protegen las especies en peligro de extinción. Preservar la eficacia de los antibióticos y mantener la susceptibilidad de los ecosistemas bacterianos deben ser objetivos globales.

© 2014 Elsevier España, S.L.U. y SEMICYUC. Todos los derechos reservados.

We must change how antibiotics are used and adopt proactive strategies, similar to those used to save endangered species. Preservation of the efficacy of antibiotics and to stabilization of antibiotic-susceptible bacterial ecosystems should be global goals.

We urge all of you to participate in this crusade, in your own field of interest. The medical miracle of antibiotic therapy must be protected – this is a global priority and our duty. Please, help us to act NOW, by supporting this declaration, to promote wiser use of antibiotics in animal and human health, and the necessary accompanying political actions to support better education, integrated surveillance for public health action, and research.

The increase in antibiotic resistant bacteria poses a major healthcare threat. In the face of an almost complete absence of new antimicrobial drugs in development, antibiotic resistance (ABR) has become one of the main public health problems of our time. Antibiotics are a unique class of medications because of their potential societal impact; use of an antibiotic in a single patient can select for ABR that can spread to other people, animals, and the environment, making an antibacterial used in one patient ineffective for many others. Bacterial resistance can evolve rapidly. As bacteria acquire resistance mechanisms, the altered bacterial...
genetic material coding for resistance mechanisms can be transmitted at times readily between bacteria, broadening the reach and extent of resistance. Treatment failures because of multiresistant (MDR) bacteria, once rare, notable, and limited to hospitals, now occur very commonly in hospitals and increasingly in the community as well. It is estimated that a minimum of 25,000 patients in Europe and 23,000 in the USA die each year from infections caused by resistant bacteria. The cost of antibiotic resistance is tremendous, whether measured as the personal and societal burden of illness, death rates, or healthcare costs.

Although it is a never-ending phenomenon, antibiotic resistance is directly related to the volume of antibiotics used. We are using increasing amounts of antibiotics in health care and agriculture, and discharging these active drugs into the environment. The impact of widespread antibiotic use is enormous, promoting the development and dissemination of antimicrobial resistance.

Safeguarding antibiotics will require a concerted effort by citizens, patients and prescribers. The primary goal of WAAAR is to raise awareness about the urgency and magnitude of the threat and to promote an international dialogue to assist in effective responses. The Alliance, in particular through this declaration, is dedicated to actively promoting antibiotic preservation and to raising awareness among antibiotic prescribers, politicians and policy-makers, patient safety and advocacy groups, the pharmaceutical industry, international health organizations, and the general population. Individual actions, no matter how well intended, are doomed to failure unless there is an international dialogue, a common sense of purpose, and broad consensus on how best to proceed.

WAAAR advocates for the following 10 actions

1. Promotion of awareness of all the stakeholders – including the general public – of the threat represented by antibiotic resistance
   - Strong cooperation among international political, economic and public health organizations, which, all together, must take the lead of this action against antibiotic resistance.

2. Organization, in each country, ideally by Ministries of Health or regulatory bodies, of a financed national plan for the containment of antibiotic resistance, with the participation of all stakeholders, including patient advocacy groups

3. Continuous access to antibiotics of assured quality, especially in middle and low-income countries

4. WAAAR advocates for the following 10 actions Integrated Surveillance of antibiotic resistance (ABR) and antibiotic use
   - Standardized monitoring of antibiotic use and resistance at institution, regional, and country (comprehensive national data instead) level (through a Centres for Diseases Control and Prevention model) to allow comparative statistics (benchmarking), to be updated preferably in real-time and at least every 12 months. This will require adequate laboratory capacity using international standardized methods that may be facilitated by a centralized technologic coordinating infrastructure and information technology

5. Use of diagnostic tests
   - Appropriate use of existing diagnostic tests and development and implementation of new rapid, cost-effective and accurate diagnostic tests, adapted to the local context, to aid in distinguishing bacterial and nonbacterial etiologies. Rapid diagnostics may help clinicians avoid unnecessary treatments, rapidly select appropriate targeted therapies and inform the duration of treatment

6. Antibiotic stewardship (prudent, controlled and monitored approaches to the use of antibiotics)
   - In humans (hospitals, long term care facilities and primary care).
   - In animals (animal husbandry, agriculture, aquaculture and animal health/veterinary setting), in a “one health” philosophy.
   - Progressive elimination of the “over the counter” (i.e. available without a prescription) access to antibiotics (systemic and topicals) for humans or animals.
   - Ban of the use of antibiotics as growth promotion in food animals, and exceptional use in prophylaxis.
   - Rational use of metaprophylaxis (Prophylaxis when some animals in the livestock are sick, or at high risk to be sick), and of animal treatment.
   - Limitation of the use of critically important antibiotics in humans and animals (e.g., carbapenems).

7. Educational efforts for change
   - Educational programmes directed at children/teenagers on antibiotics, bacterial resistance, and infection control (e-Bug model).
   - Development of large coordinated, effective information and awareness campaigns directed at the public on expectations about the rational/appropriate use of antibiotics.
   - Continuous education and training programmes in the curriculum for all health care professionals in all settings (veterinarians, medical, dental, nursing, pharmacy and allied health care schools) and continuing professional education programmes, on the rational use of antibiotics, including indications, dosing and duration of therapy. Education of farmers.

8. Containment of bacterial transmission and prevention of infection
   - Promotion of universal hand hygiene and all infection control interventions that have been proven to reduce rates of resistance.
   - Relentless efforts to prevent transmission of MDR organisms in healthcare, food production and animal husbandry.
   - Programmes to limit the contamination of drinking water with MDR bacteria, as well as contamination of the environment.
   - Promotion of the use of available vaccines, in humans and animals.

9. Basic and applied research, and development of new antibiotics
   - Increased support for basic and applied research aiming at curbing bacterial resistance in human and veterinary medicine.
• Use of the principles of orphan drugs for new antibiotics.
• Incentives to stimulate research of new drugs (antibiotics and novel compounds) and vaccines via regulatory pathways that allow for fast track development.
• New economic business models to support the cost of innovation while safeguarding public health interests.

10. Request for UNESCO to include the “concept of antibiotic” in the list of the intangible cultural heritage.

Funding
No funding.

Conflict of interest
No conflict of interest.

Appendix.

WAAAR is a group of 700 individuals from 55 different countries representing all the key stakeholders (physicians, veterinarians, microbiologists, surgeons, pharmacists, nurses, evolutionary biologists, ecologists, environmentalists, patient advocacy groups). The Alliance receives support from more than 140 learned societies or professional groups throughout the world. WAAAR is a nonprofit organization open to professionals and consumers worldwide. WAAAR receives no funding from the pharmaceutical industry.

Supporting individuals
Laurent Aaron (France), Mohamed Salah Abassi (Tunisia), Lilian Abbo (USA), Oladipo Aboderin (Nigeria), Edward Abrahall (USA), Fekri Abroug (Tunisia), Jacques Acker (France), Wafa Achour (Tunisia), Javier Adachi (USA), Seif Al-Abri (Oman), Hafsa Al-Mousa (Kuwait), Antonio Albayda-Moreno (Spain), Corinne Alberti (France), Serge Alfandari (France), Amani Alnimir (Saudi Arabia), Celia Alpuget Aranda (Mexico), Francisco Alvarez de Lerm (Spain), Fatma Amer (Egypt), Antoine Andreffl (France), François Angoulvant (France), Maryvonne Anguill (France), Massimo Antonelli (Italy), Eleni Antoniadou (Greece), Guillaume Arlet (France), Apostolos Armaganidis (Greece), Anne Arnera (France), Antonio Artigas (Spain), Claude Attali (France), Frédéric Aubert (France), Jean-Pierre Aubert (France), Bernard Augereau (France), Martine Aupée (France), Olfa Bahri (Tunisia), Françoise Ballerée (France), Gérard Bapt (France), Fernando Baquero (Spain), Timothy Barkhan (Singapore), Ouahid Barouti (Morocco), Marie-Anne Barthelemy (France), Greg Barton (UK), Davide Bastoni (Italy), Michel Baussier (France), Luis Bavestrello (Chile), Birgit Beger (Belgium), Samuel Benenson (Israel), Fethi Bensalem (France), Guillaume Béraud (France), Frédérique Bertheau (France), Gordon Bernard (USA), Philippe Berthelot (France), Xavier Bertrand (France), Frédérique Beuhory-Sassus (France), Pascal Beuret (France), John Billington (USA), Jacques Birgé (France), Sandra Biscardi (France), Luis Blanch (Spain), Hervé Blanchard (France), Thomas Bleck (USA), Joseph Blondeau (Canada), François Blot (France), France Borgey (France), Alain Bousquet-Méhou (France), Jean Bram (France), Christophe Brard (France), Stéphane Bretegne (France), Cédric Bretonnière (France), Adrian Brink (South Africa), Sheldon Brown (USA), Catherine Brunt-Rodier (France), Christian Brun-Buiss (France), Fabrice Bruneel (France), Frederico Bruzzi de Carvalho (Brazil), Christophe Bueno (France), Huda Bukhari (Saudi Arabia), André Cabie (France), Thierry Calandra (Switzerland), Isabelle Caniaux (France), Manuela Canica (Portugal), Rafael Canton (Spain), Philippe Careno (France), Camille Carlet (France), Claude Carlet (France), Florian Carlet (France), Jean Carlet (France), Romain Carlet (France), Otto Cars (Sweden), Manuel Cassiano-Neves (Portugal), Bernard Castan (France), Vincent Castellan (France), France Cazenave-Roblot (France), Alain-Michel Ceretti (France), Jean-Charles Chakarian (France), Ludvine Chalumeau-Lemoine (France), John Chand (USA), Bernard Chanfreau (France), Jean Chastre (France), Robert Chausset (France), Pascal Chavanet (France), William Cheddle (USA), Jean-Daniel Chiche (France), Christian Chidiac (France), Olivier Chosidow (France), Natalia Chueca (Spain), Jon Cohen (UK), Robert Cohen (France), Peter Collignon (Australia), Frédéric Collot (France), Patrick Coloby (France), John Conly (Canada), Cruz Cordero (Brazil), Catherine Cordonnier (France), Alejandra Corso (Argentina), Sara Cosgrove (USA), René Courcol (France), Steve Crane (USA), Donald Craven (USA), Adina Crespin (France), Marcys Cyrillo (Brazil), Pierre-Eric Danin (France), Jan De Waele (Belgium), Pierre Dellamonica (France), E. Patchen Dellinger (USA), Philip Dellingr (USA), Jean Demont (France), Eric Denes (France), George Dimopoulos (Greece), Dimitri Drekonja (USA), Anah Dreser Mansilla (Mexico), Pierre-Louis Druais (France), Sylvie Dufour-Pierrrat (France), Catherine Dumartin (France), Martin Düns (Austria), Michel Dupont (France), Ricardo Durlach (Argentina), Oliver Dyer (UK), Gabriela Echaniz (Mexico), Paul Edelstein (USA), Philippe Eggimann (Switzerland), Mohamed Elghomni (Egypt), Naima Elmghareh (Morocco), Rehab Elsaid (Egypt), Rehab Elsokari (Egypt), Dan Engelhard (Israel), Jacques Fabry (France), Christopher Farmer (USA), J. Fernández (Spain), Simon Finfer (Australia), Patricia Finn (USA), Katrin Fjeldsted (Israel), Daniel Floret (France), Francesco Flocoro (Spain), Jacinthe Foegle (France), Xavier Forgeville (France), Sandra Fournier (France), Irène Frachon (France), Alexander Friedrich (The Netherlands), Pascal Funel (France), Didier Gaillard (France), Jacques Gaillant (France), Tatiana Galperine (France), Karine Gamarotto (France), Bernard Garo (France), Maité Garrouste-Orgeas (France), Petra Gastmeier (Germany), Jean-Yves Gauchot (France), Remy Gauzit (France), Gaëtan Gavazzi (France), Louise Gagone (France), Julie Gerberding (USA), Abdul Ghalfor (India), Evangelos Giamarelos-Bourboulis (Greece), Eleini Giamarellou (Greece), Marine Giard (France), Mark Gilchrist (UK), Jacques Gilquin (France), Fernando Gilsanz (Spain), Marek Gniadkowski (Poland), Charalampos Gogos (Greece), Don Goldman (USA), Florence Gordon (France), Thomas Gotlib (Australia), Ian Gould (UK), Joao Gouveia (Portugal), Jennifer Grant (Canada), Lindsay Grason (Australia), Ailx Greder (France), Hajo Grundman (The Netherlands), Eric Guaguere (France), Gwenaelle Guéroult-Locher (France), Benoit Guery (France), Bertrand Guidet (France), Catherine Guignabert (France), Pradip Gupta (India), Sanjay Gupta
Finn, Steve Crane), Analgesia and Intensive Care Medicine (SIAARTI) (Massimo Antonelli), Andalusian Infectious Diseases Society (Jesus Gomes Mateos), Asia Pacific Society of Infection Control (APSIC) (Ling Moi Lin), Associação de Medicina Intensiva Brasileira (AMIB) (Jose Mario Meira Teles), Association Française d’Urologie (AFU) (Patrick Coloby), Association Française de Chirurgie (Jean Pierre Arnaud), Association Française des Vétérinaires pour Animaux de Compagnie (AFVAC) (Eric Guaguère, Jean-François Rousselot), Association of Physicians of India (Dr Muruganathan), Association Tunisienne de Réanimation (ATR) (Fekri Abrough), Association Vétérinaire Equine Française (AVEF) (Jean-Yves Gauchot), Australasian Society for Infectious Diseases (ASID) (David Looke), Australian Society for Antimicrobials (ASA) (Thomas Gottlieb), Belgian Society of Intensive Care Medicine (SIZ) (Alexander Wilmer), Belgian Infection Control Society (BICS) (Hilde Jansens), Brazilian Society of Infectiology, British Infection Association (Albert Mifsud), British Society of Antimicrobial Chemotherapy (Nicholas Brown, Laura Piddock), Centre National de Référence de la Résistance aux Antibiotiques (Patrick Pléiat), Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias (SEMICYUC) (Luís Blanch, Miguel Sanchez Garcia, Francisco Alvarez Lerma), Egyptian Society for Infection Control (ESIC) (Ossama Rassan), European Federation of National Associations of Orthopaedics and Traumatology (Manuel Cassiano-Neves), European Society of Infectious Diseases and Clinical Microbiology (ESCMID) ( Gunnar Kahlmeter, Murat Akova), European Society of Intensive Care Medicine (ESICM) (Jean Daniel Chiche), Fédération Française de Pneumologie (Bruno Houssset), Federation of European Microbiological Societies (FEMS) (Bauke Oudega), Federation of Infectious Diseases Societies of Southern Africa (Marc Mendelson), Federation Vétérinaire Européenne (FVE) (Christophe Buhot, Jan Vaarten), German Interdisciplinary Association of Intensive and Emergency Medicine ( Dietmar Schneider, Michael Quintel, Elke Muhl), Hellenic Society of Antimicrobial Chemotherapy (Helen Giamarellou), Hellenic Society of Intensive Care (Antonios Pavrommatis), Ho Chi Minh City Infection Control Society (Thi Anh Thu Le), Indian Medical Association (Narendra Saini, K. Vijayakumar), Infection Control Association of Singapore (ICAS) (Ling Moi Lin), Instituto Latino-Americano de Sepsis (ILAS) (Reinaldo Salomao), International Society of Chemotherapy (Ian Gould), International Society of Infectious Diseases (ISID) (Jon Cohen, Keith Klugman), Israel Society for Infectious Diseases, Italian Society of Anesthesiology, Korean Society of Clinical Microbiology (Nam Yong Lee), Lebanese Association for Medical Diagnosis and Auto-Immune Diseases (Lamba) (Georges Khalil), Pan American Society of Infectious Diseases (Luís Vestrelstro), Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. (Paul-Ehrlich-Society for Chemotherapy) (Achim Hoerauf), Polish Society of Anesthesiology and Intensive Care (Magolia Mikaszewska-Sokolewicz), Portuguese Society of Infectious Diseases and Clinical Microbiology (Helena Ramos), Portuguese Society of Intensive Care (Joao Gouveia, Ricardo Matos), Saudi Society of Medical Microbiology and Infectious Diseases (Huda Bukharie), Sociedad Española de Enfermedades Infecciosas y Microbiología Clinic (SEIMC) (Jose M Miro), Sociedad Española de Enfermedades Respiratorias (SEPAR) (Pilar de Lucas), Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias (SEMICYUC) (Luís Blanch, Miguel Sanchez Garcia, Francisco Alvarez Lerma, Pedro Maria Olachea), Society for Healthcare Epidemiology of America (SHEA) (Melanie Young), Societé Paulista de Infectologia-Brazil (Rosana Richman), Société Belge de Microbiologie Clinique (BVIK/SBIMC) (Camelia Rossii), Société de Pathologie Exotique (Jean Delmont), Société de Pathologie Infectieuse de Langue Française (SPLIF) (Christian Rabaud), Société de Pneumologie de Langue Française (SPLF) (Alain Didier), Société de Réanimation de Langue Française (SRFL) (Djillali Annane), Société Française d’Anesthésie Réanimation (SFAR) (Claude Ecoffey), Société Française d’Hygiène Hospitalière (SFZH) (Philippe Berthelot), Société Française de Chirurgie Orthopédique et Traumatologique (Bernard Augereau), Société Française de Dermatologie (SFDD) (Olivier Chosiow), Société Française de Gériatrie et Gérontologie (SFGG) (Geneviève Ruault), Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGTM) (Ibrahim Yacoub), Société Française de Médecine Générale (SFMG) (Pascale Arnould), Société Française de Médicine Interne (SFMI) (Loic Guillevin), Société Française de Microbiologie (SFM) (René Courcol), Société Française de Pharmacie Clinique (SFPC) (Marie-Claude Saux, Remi Varin), Société Française de Santé Publique (SFSP) (Pierre Lombrait), Société Libanaise de Médecine Interne (SLMI) (Emile Zein), Société Marocaine d’Hypothèse Hospitalière (Ouahid Barouti), Société Marocaine de Maladies Infectieuses (SMMI), Société Nationale des Groupements Techniques Vétérinaires (SNGTV) (Christophe Brard), Société Tunisienne de Pathologie Infectieuse (STPI), Society of Critical Care Medicine (SCCM) (Chris Farmer, David Martin), Society of Infectious Diseases of Singapore (Paul Ananchara Jambiyab), Société Suisse d’Infectiologie (Bernard Hirschel), Spanish Society of Anesthesiology and Critical Care (Fernando Gilsanz, Emilio Maseda), Spanish Society of Infectious Diseases and Clinical Microbiology (José Miro, Rafael Canton), Standing Committee of European Doctors (Katrin Fjeldsted, Birgit Beger), Surgical Infection Society (SIS) (William Cheadle), The Infectious Diseases Society of America (IDSA) (John Billington, David Relman), The Mexican Society of Infectious Diseases and Clinical Microbiology (AMIMC) (Celia Alpuche Aranada), Thoracic Society of Australia and New Zealand (Matthew Peters, Peter Wark), United Kingdom Clinical Pharmacy Association (UKCPA) (Mark Borthwick), World Federation of Societies of Intensive Care and Critical Care Medicine (WFSICCM) (Jean-Louis Vincent).

Other supporting groups
Antibiolor (C. Rabaud), Antimicrobial Stewardship Working Group of the International Society of Chemotherapy (ISC) (Gabriel Levy Harra), Arab Alliance for a Prudent Use of Antimicrobials (Ar-Apua) (Fatma Amer), Association of Lutte contre les Infections Associées aux Soins (ALIAS), Association des Médecins Coordonnateurs en EHPAD, Association des Victimes d’Infection Nosocomiale (ADVIN), Association Le CISS (Claude Rambaud), Association Le Lien (Madeleine Madoré), Association Phagespoir (Jérôme Larchet), Association pour la Chimiorthérapie Anti-infectieuse (AACA), Association pour la Recherche en Microbiologie Expérimentale (Marie-Laure Joly-Guillou), Austrian Antibiotic Stewardship Group (Elisabeth Heising), CCLIN Ouest (Martine Aupée), Centre for Infection Control and the APIC-Saudi chapter (Hanah Balkhy), Chaire Recherche Infirmière, AP-HP EHESS (France,
Monique Rothan-Tondeur), Collège des Enseignants de Maladies Infectieuses (CMIT) (Christian Michelet), Collège National de Médecine Générale (CNMG), Collège National des Généralistes Enseignants (CNGE) (Pierre Louis Druais), Comité de Pilotage des Réseaux de Surveillance ATB et BMR Sud Est, Doctors Without Borders/Médecins Sans Frontières (Arthène Chua, Richard Murphy), Egyptian Patient Safety Association (EPSA) (Ossama Rassla), ESGAP working group (ESCMID) (Jordi Rello), Fédération des Spécialités Médicales (FSM), Fédération Française d’Infectiologie (FFI) (Christian Perrone), Fédération Française de Pneumologie (FFP) (Bruno Housset), Global Sepsis Alliance (Konrad Reinhart), Groupe de Pathologie Infectieuse en Pédriatre (GPIP) (Robert Cohen), Grupo de Infeccao e Sepsis (Joao Jaime Sa), Grupo de Trabajo de Enfermedades Infecciosas y Sepsis De la Sociedad Española de Medicina Intensiva, Hellenic Sepsis Study Group (Gogos Charalambos, Evangelos Giamarelos-Bourboulis), Infection Control Directorate (Ministry of Health-Kuwait), Infection Prevention and Control African Network (IPCAN) (Shaheen Mehtar), Institut de Recherche en Médecine Générale (IRMG), Institut Maurice Rapin (IMR) (Christian Brun-Buisson), International Forum for Acute Care Trialists (InFACT) (John Marshal), International Sepsis Forum (Tom Van Der Poll), Le Forum des Bio-hygienistes, Ligue Africaine des Associations pour la Sécurité des Patients (LIASEP), Medqual (F. Balkerereau), National Committee for the Proper Use of Antimicrobials (Ministry of Health-Kuwait), Observatoire du Risque Infectieux en Gériatrie (ORIG) (Monique Rotha-Tondeur), Observatoire National d’Epidémiologie de la Resistance Bactérienne aux antibiotiques (ONERBA) (Marie-Hélène Nicolas-Chanoine), Portuguese Intersectorial Alliance for the Preservation of the Antibiotics (APAPA) (Jose Arthur Paiva), Programme National de Lutte contre l’Infection Nosocomiale (PRONALIN), Sénégal (Babacar N’Doye), Réseau International pour la Planification et l’Amélioration de la Qualité des Soins en Afrique (RIPAQS) (Bernard Chanfreau), Réseau Sud-Est de Surveillance et de Prévention des Bactéries Multi-résistantes aux Antibiotiques, South African Antibiotic Stewardship programme (Adrian Brink), Spanish Network for Research in Infectious Diseases (REIPI) (Jesus Rodriguez-Bano), Safe Observer International (SOI) (Garance Upham), The Bekele Afessa Initiative to Improve Sepsis Care in Resource-Limited Areas (Joseph Christopher Farmer), The Canadian Antimicrobial Resistance Alliance (CARA), The Eastern Mediterranean Regional Network for Infection Control (EMRN) (Ossama Rassla), The Gulf Cooperation council (GCC) (Hanan Balkhy).